Teva/Eisai rasagiline deal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai will co-promote Teva's MAO-B inhibitor rasagiline in North America for Parkinson's disease under a deal that also calls for global co-development for Alzheimer's disease. Teva recently announced successful completion of its Phase III Parkinson's program, with an FDA filing set for second half 2003 (1Pharmaceutical Approvals Monthly May 1, p. 14)...
Eisai will co-promote Teva's MAO-B inhibitor rasagiline in North America for Parkinson's disease under a deal that also calls for global co-development for Alzheimer's disease. Teva recently announced successful completion of its Phase III Parkinson's program, with an FDA filing set for second half 2003 (1 Pharmaceutical Approvals Monthly May 1, p. 14).... |